113 related articles for article (PubMed ID: 38564070)
1. ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.
Omura M; Kosaka T; Kobayashi H; Shigeta K; Matsumoto K; Hara S; Kikuchi E; Mikami S; Saya H; Sato Y; Oya M
Ann Surg Oncol; 2024 Jun; 31(6):3914-3915. PubMed ID: 38564070
[No Abstract] [Full Text] [Related]
2. A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1.
Yan Y; Shen Z; Ye Y; Jiang K; Zhang H; Shen C; Mustonen H; Puolakkainen P; Wang S
Med Oncol; 2014 Feb; 31(2):816. PubMed ID: 24366689
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of vasohibin-1 and vasohibin-2 immunohistochemical expression in gastric cancer.
Hara H; Ozawa S; Ninomiya Y; Yamamoto M; Ogimi M; Nabeshima K; Nakamura K; Kajiwara H; Nakamura N; Sato Y
Surg Today; 2020 Nov; 50(11):1530-1543. PubMed ID: 32494966
[TBL] [Abstract][Full Text] [Related]
4.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
5. Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.
Omura M; Kosaka T; Kobayashi H; Shigeta K; Matsumoto K; Hara S; Kikuchi E; Mikami S; Saya H; Sato Y; Oya M
Ann Surg Oncol; 2024 May; 31(5):2951-2958. PubMed ID: 38376711
[TBL] [Abstract][Full Text] [Related]
6. ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
Ślusarczyk A
Ann Surg Oncol; 2024 Jun; 31(6):3910-3911. PubMed ID: 38602577
[No Abstract] [Full Text] [Related]
7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Mori K; Schuettfort VM; Egawa S; Compérat E; Shariat SF
Ann Surg Oncol; 2022 Aug; 29(8):5317-5318. PubMed ID: 35412203
[No Abstract] [Full Text] [Related]
9. Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.
Jia Y; Ding X; Zhou L; Zhang L; Yang X
Oncogene; 2021 Jan; 40(2):246-261. PubMed ID: 33122828
[TBL] [Abstract][Full Text] [Related]
10. Cell Cycle Markers in the Evaluation of Bladder Cancer.
da Silva JNL; Ranzi AD; Carvalho CT; Scheide TV; Strey YTM; Graziottin TM; Bica CG
Pathol Oncol Res; 2020 Jan; 26(1):175-181. PubMed ID: 29524168
[TBL] [Abstract][Full Text] [Related]
11. miRNA 21: a novel biomarker in the treatment of bladder cancer.
Sekar D
Biomark Med; 2020 Aug; 14(12):1065-1067. PubMed ID: 32969249
[No Abstract] [Full Text] [Related]
12. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
13. [Histochemical expression of proliferating cell nuclear antigen (PCNA) for pre and post chemotherapeutic bladder cancer].
Nagase Y; Moriyama N; Kurimoto S; Tajima A; Higashihara E; Aso Y
Nihon Hinyokika Gakkai Zasshi; 1995 May; 86(5):985-90. PubMed ID: 7596084
[TBL] [Abstract][Full Text] [Related]
14. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
Bazargani ST; Clifford TG; Djaladat H; Schuckman AK; Wayne K; Miranda G; Cai J; Sadeghi S; Dorff T; Quinn DI; Daneshmand S
Urol Oncol; 2019 Jan; 37(1):1-11. PubMed ID: 30470611
[TBL] [Abstract][Full Text] [Related]
15. ASO Author Reflections: Advancing Early Outcome Assessment in Robot-Assisted Radical Cystectomy: RARC Tetrafecta.
Song W; Yu J; Jeong BC
Ann Surg Oncol; 2024 Jun; 31(6):3908-3909. PubMed ID: 38536582
[No Abstract] [Full Text] [Related]
16. Emerging therapeutic targets in bladder cancer.
Carneiro BA; Meeks JJ; Kuzel TM; Scaranti M; Abdulkadir SA; Giles FJ
Cancer Treat Rev; 2015 Feb; 41(2):170-8. PubMed ID: 25498841
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.
Ru Y; Dancik GM; Theodorescu D
Curr Opin Urol; 2011 Sep; 21(5):420-7. PubMed ID: 21814055
[TBL] [Abstract][Full Text] [Related]
18. Reduced ING4 Expression Is Associated with the Malignancy of Human Bladder.
Wang Y; Wang T; Han Y; Wu H; Zhao W; Tong D; Wei L; Zhong Z; An R; Wang Y
Urol Int; 2015; 94(4):464-71. PubMed ID: 25790869
[TBL] [Abstract][Full Text] [Related]
19. Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.
Fukushima H; Takemura K; Suzuki H; Koga F
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30275370
[TBL] [Abstract][Full Text] [Related]
20. The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Rose M; Noetzel E; Kistermann J; Eschenbruch J; Rushrush S; Gan L; Knüchel R; Gaisa NT; Dahl E
Cells; 2021 Apr; 10(5):. PubMed ID: 33924987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
